Brenntag brings Lipomed’s natural CBD to EMEA region

Lipomed’s plant-based and GMP-compliant Cannabidiol will be available to customers in EMEA through Brenntag Specialties.

Brenntag is collaborating with Lipomed to introduce a CBD Pure API to the pharma industry in EMEA. The exclusive partnership with the Swiss life science company will see its crystalline powder containing cannabidiol derived from plants made available to pharma manufacturers in the region.

The plant extracts used to produce the Natural CBD Pure API originate from a certified Swiss hemp of the genetics Cannabis sativa L. and are obtained through a gentle low-temperature extraction process. It contains over 98.5% pure CBD and has close to zero (≤0.10%) delta-9-tetrahydrocannabinol (THC), preservatives, and artificial additives. Unlike THC, which is known for its psychoactive effects, CBD is non-intoxicating and suitable to be used in non-narcotic pharmaceutical applications. Complying with international pharmaceutical standards, Natural CBD Pure API offers a reliable and high-quality solution to the pharmaceutical industry. It can also be used to produce customised formulations. 

A beneficial collaboration

Christoph Conrad, Head of Industry Market Management APIs & Supplements at Brenntag Specialties, remarked: “Lipomed’s high purity CBD is a perfect addition to our API portfolio in EMEA. As Brenntag always strives to work with the best and most trustworthy partners and materials of the industry, there could not be a better fit than Lipomed. These products combine natural origin, highest purity, and Swiss pharma expertise. We are very proud of the trust and confidence we are receiving with this exclusive partnership, and we are sure that together we will create a significant contribution to the development of the pharmaceutical market in EMEA.”   

Dr. Athanasios Zikopoulos, CEO of Lipomed, added: “We are delighted and proud to join forces with such a reputed and skilled partner as the Brenntag team for the commercialisation and distribution of our Natural CBD Pure API in the EMEA region. This marks the beginning of a certainly fruitful cooperation that will benefit both parties and their customers.”